Research Article
BibTex RIS Cite

Geri çekildi: Hepatit B VE Hepatit C Virüsleriyle Karşılaşmış Olan Böbrek Nakilli Hastaların Klinik Seyrinin İzlenmesi

Year 2019, Volume: 14 Issue: 2, 57 - 62, 31.05.2019

Abstract


Bu makale 30-09-2021 tarihinde geri çekildi. https://dergipark.org.tr/tr/pub/hemsire/issue/65182/1003121 

Giriş: Böbrek nakilli hastalarda Hepatit B (HBV) ve
Hepatit C (HCV) sıklığını saptamak ve HBV, HCV olan ve olmayan hastalarda renal
fonksiyonların, klinik seyirlerin karşılaştırılması amaçlanmıştır.

Gereç ve Yöntemler: 2008 – 2016 yılları
arasında böbrek nakil ünitesinde takip edilen hastalar geriye dönük olarak
incelendi. Hepatit serolojileri, hastaların demografik, klinik ve laboratuvar
bulguları kayıt edildi. HBV, HCV olan hastalar ile aynı dönemde nakil olmuş
HBV, HCV olmayan hastalarla kontrol grubu oluşturularak verileri
karşılaştırıldı.

Bulgular : Toplam 872 hastanın 15 ‘inde (%1,7) HBV (9E,
ortalama yaş 42±11 yıl, ortalama izlem süresi 56,6±26 ay), 20'sinde(%2,3) HCV
(15E, ortalama yaş 50,6±14,9 yıl, ortalama izlem süresi 46,6±28,2 ay), olduğu
görüldü. Kontrol grubuna 35 hasta (23E, ortalama yaş 47±10,4 yıl, ortalama
izlem süresi 51,4±24,3 ay) alındı. Gruplar arasında yaş, cinsiyet ve takip
süresi açısından anlamlı fark saptanmadı (sırasıyla p:0.12, 0.62,0,52). HBV
hastalarının %53,3'ünde , kontrol grubunun ise %60'ında indüksiyon tedavisi
olarak Anti timosit globulin(ATG) kullanılırken HCV hastalarının %75'inde
Simulect kullanımı saptandı. İdame tedavisi olarak steroid+MMF/MMY+kalsinörin
inh kullanımı vardı ve gruplar arasında anlamlı fark yoktu (p<0,05). HCV
olan hastaların %11,7'sinde, kontrol grubu hastalarının %9,3'ünde nakil sonrası
diyabet ortaya çıktığı gözlendi. HBV olan hastalarda ise diyabet gözlenmedi.







Sonuç olarak böbrek nakilli hastalarda hepatit
varlığının (HBV,HCV) hastalığın klinik seyri üzerine etkisi saptanmadı. HCV
olan hastalarda yeni diyabet gelişimi açısında dikkatli olunmalıdır.

References

  • Referans1-Einollahi B, Hajarizadeh B, Bakhtiari S, et al. Pretransplant hepatitis C virus infection and its effect on the posttransplant course of living renal allograft recipients. J Gastroenterol Hepatol. 2003;18:836-40.
  • Referans2-Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.
  • Referans 3- Botelho SM, Ferreira RC, Reis NR, et al. Epidemiological aspects of hepatitis C virus infection among renal transplant recipients in Central Brazil. Mem Inst Oswaldo Cruz. 2008;103:472-6.
  • Referans 4- Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: metaanalysis of observational studies. Am J Transplant 2005; 5: 1452.
  • Referans 5-Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group.KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155.
  • Referans 6.Hepatitis C: Surveillance and Control [İnternet]. Geneva: World Health Organization. http://www.who.int/ csr/disease/hepatitis/whocdscsrlyo2003.
  • Referans 7. Karkar A. Hepatitis C in dialysis units: the Saudi experience. Hemodial Int. 2007; 11(3): 354-67.
  • Referans 8.Aygen B, Utaş C, Özbakır Ö, Düşünsel R, Doğanay M, Yücesoy M. Prevalence of HCV antibody in hemodialysis patients: correlation with ALT and hepatitis B serological markers [Abstract]. In: FEMS Symposium on the Hepatitis C Virus and Its Infection (29 June-01 July 1993, İstanbul, Turkey) Abstracts. İstanbul: Turkish Microbiological Society, 1993: 40. 16
  • Referans 9.Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005; 18(1): 52-61.
  • Referans 10. Süleymanlar G, Ateş K, Seyahi N et al. Türkiye 2016 Yılı Ulusal Nefroloji, Diyaliz ve Transplantasyon Kayıt Sistemi Raporu. http://www.nefroloji.org.tr/folders/file/2016_REGISTRY.pdf
  • Referans11. Rao KV, Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996; 62: 1765.
  • Referans12. Legendre C, Garrigue V, Le Bihan C, et al. Harmful longterm impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667.
  • Referans 13. Sezer S, Ozdemir FN, Akcay A, et al. Renal transplantation offers a better survival in HCV infected ESRD patients. Clin Transplant 2004; 18: 619-23.
  • Referans 14. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001; 72: 241-4.
  • Referans 15. Kliem V, van den Hoff U, Brunkhorst R, et al. The longterm course of hepatitis C after kidney transplantation. Transplantation 1996; 62: 1417-21.
  • Referans 16. Alavian SM. Re: Posttransplant Diabetes Mellitus in Kidney Allograft Recipients at Shaheed Hasheminejad Hospital. Iran J Kidney Dis.2008;2:110-1.
  • Referans 17. Fabrizi F, Lampertico P, Lunghi G, Mangano S, Aucella F, Martin P. Review article: hepatitis C virus infection and type-2 diabetes mellitus in renal diseases and transplantation. Aliment Pharmacol Ther.2005;21:623-32.
  • Referans 18. Gentil MA, Lopez M, Gonzalez-Roncero F, et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: influence of new immunosuppression protocols.Transplant Proc.2003;35:1748-50.
  • Referans 19. Hathout EH, Chinnock RE, Johnston JK,et al.Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients. Am J Transplant.2003 3:994-8.
Year 2019, Volume: 14 Issue: 2, 57 - 62, 31.05.2019

Abstract

References

  • Referans1-Einollahi B, Hajarizadeh B, Bakhtiari S, et al. Pretransplant hepatitis C virus infection and its effect on the posttransplant course of living renal allograft recipients. J Gastroenterol Hepatol. 2003;18:836-40.
  • Referans2-Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.
  • Referans 3- Botelho SM, Ferreira RC, Reis NR, et al. Epidemiological aspects of hepatitis C virus infection among renal transplant recipients in Central Brazil. Mem Inst Oswaldo Cruz. 2008;103:472-6.
  • Referans 4- Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: metaanalysis of observational studies. Am J Transplant 2005; 5: 1452.
  • Referans 5-Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group.KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155.
  • Referans 6.Hepatitis C: Surveillance and Control [İnternet]. Geneva: World Health Organization. http://www.who.int/ csr/disease/hepatitis/whocdscsrlyo2003.
  • Referans 7. Karkar A. Hepatitis C in dialysis units: the Saudi experience. Hemodial Int. 2007; 11(3): 354-67.
  • Referans 8.Aygen B, Utaş C, Özbakır Ö, Düşünsel R, Doğanay M, Yücesoy M. Prevalence of HCV antibody in hemodialysis patients: correlation with ALT and hepatitis B serological markers [Abstract]. In: FEMS Symposium on the Hepatitis C Virus and Its Infection (29 June-01 July 1993, İstanbul, Turkey) Abstracts. İstanbul: Turkish Microbiological Society, 1993: 40. 16
  • Referans 9.Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005; 18(1): 52-61.
  • Referans 10. Süleymanlar G, Ateş K, Seyahi N et al. Türkiye 2016 Yılı Ulusal Nefroloji, Diyaliz ve Transplantasyon Kayıt Sistemi Raporu. http://www.nefroloji.org.tr/folders/file/2016_REGISTRY.pdf
  • Referans11. Rao KV, Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996; 62: 1765.
  • Referans12. Legendre C, Garrigue V, Le Bihan C, et al. Harmful longterm impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667.
  • Referans 13. Sezer S, Ozdemir FN, Akcay A, et al. Renal transplantation offers a better survival in HCV infected ESRD patients. Clin Transplant 2004; 18: 619-23.
  • Referans 14. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001; 72: 241-4.
  • Referans 15. Kliem V, van den Hoff U, Brunkhorst R, et al. The longterm course of hepatitis C after kidney transplantation. Transplantation 1996; 62: 1417-21.
  • Referans 16. Alavian SM. Re: Posttransplant Diabetes Mellitus in Kidney Allograft Recipients at Shaheed Hasheminejad Hospital. Iran J Kidney Dis.2008;2:110-1.
  • Referans 17. Fabrizi F, Lampertico P, Lunghi G, Mangano S, Aucella F, Martin P. Review article: hepatitis C virus infection and type-2 diabetes mellitus in renal diseases and transplantation. Aliment Pharmacol Ther.2005;21:623-32.
  • Referans 18. Gentil MA, Lopez M, Gonzalez-Roncero F, et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: influence of new immunosuppression protocols.Transplant Proc.2003;35:1748-50.
  • Referans 19. Hathout EH, Chinnock RE, Johnston JK,et al.Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients. Am J Transplant.2003 3:994-8.
There are 19 citations in total.

Details

Primary Language Turkish
Subjects Nursing
Journal Section Article
Authors

Saliha Mert

Ayşe Sinangil This is me

Soykan Barlas This is me

Zuhal Atan Uçar This is me

Yener Koç This is me

Tevfik Ecder This is me

Emin Barış Akın This is me

Publication Date May 31, 2019
Published in Issue Year 2019 Volume: 14 Issue: 2

Cite

Vancouver Mert S, Sinangil A, Barlas S, Atan Uçar Z, Koç Y, Ecder T, Akın EB. Geri çekildi: Hepatit B VE Hepatit C Virüsleriyle Karşılaşmış Olan Böbrek Nakilli Hastaların Klinik Seyrinin İzlenmesi. JoNN. 2019;14(2):57-62.

Journal of Nephrology Nursing is licensed  Creative Commons Licenseunder a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.